Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |
PMID | |
Authors | Sreerupa Valli Challa, Shenghua Zhou, Anjaneyulu Sheri, Seetharamaiyer Padmanabhan, Geeta Meher, Rayomand Gimi, Diane Schmidt, Dillon Cleary, Nezam Afdhal, Radhakrishnan Iyer |
Title | Preclinical studies of SB 11285, a novel STING agonist for immuno-oncology. |
Journal | |
Vol | |
Issue | |
Date | |
URL | https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14616 |
Abstract Text | Journal of Clinical Oncology 35, no. 15_suppl |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SB 11285 | SB11285|SB-11285 | STING1 Agonist 9 | SB 11285 is an agonist of Stimulator of Interferon Genes (STING1), which potentially activates immune cells resulting in anti-tumor immunity (Journal of Clinical Oncology 2017 35:15_suppl, e14616, PMID: 31355488). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | colon carcinoma | not applicable | SB 11285 | Preclinical | Actionable | In a preclinical study, treatment with SB 11285 delayed tumor growth and reduced tumor volume in a syngeneic mouse model of colon carcinoma (Journal of Clinical Oncology 2017 35:15_suppl, e14616). | detail... |
Unknown unknown | lymphoma | not applicable | Cyclophosphamide + SB 11285 | Preclinical | Actionable | In a preclinical study, Cytoxan (cyclophosphamide) and SB 11285 combination treatment delayed and inhibited tumor growth in a syngeneic mouse model of lymphoma (Journal of Clinical Oncology 2017 35:15_suppl, e14616). | detail... |
Unknown unknown | colon carcinoma | not applicable | SB 11285 + unspecified CTLA4 antibody | Preclinical | Actionable | In a preclinical study, treatment with SB 11285 combined with an anti-CTLA4 antibody delayed tumor growth and reduced tumor volume in a syngeneic mouse model of colon carcinoma (Journal of Clinical Oncology 2017 35:15_suppl, e14616). | detail... |
Unknown unknown | lymphoma | not applicable | SB 11285 | Preclinical | Actionable | In a preclinical study, treatment with SB 11285 delayed and inhibited tumor growth in a syngeneic mouse model of lymphoma ournal of Clinical Oncology 2017 35:15_suppl, e14616). | detail... |